LGC Capital Announces Closing of Investment in Italian Cannabis Producer, Evolution
MONTREAL, May 29, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) announces it has closed its previously announced transaction with 9379-1432 Québec Inc., the Canadian incorporated parent company of Evolution BNK and Evolution ATM (collectively referred to as “Evolution”).
On 13 August 2018, LGC and Evolution entered into a convertible debenture indenture agreement (the “Loan”) for Euro 3 million. The Loan, the proceeds of which have been paid over to Evolution, is convertible into a 49% equity interest in Evolution and bears interest at the rate of 10%.
Evolution is a legal cannabis (less than 0.2% THC) cultivation facility based in Pavia, Italy. Evolution is completing the retrofit of its 22,000 sq. ft. indoor facility within their 70,000 sq. ft. compound in Pavia, Italy for the production of high CBD, low (<0.2%) THC cannabis. Tests have been consistently positive as the product is well within the legal THC content set by the Italian Ministry of Health. Estimated margins will be greater than 50% due to its patented energy usage technology and is well placed for any margin compression expected in Europe.
Mazen Haddad, CEO LGC Capital “The value driver for Evolution is its low cost cultivation capacity which may offer synergistic benefits for other LGC investee companies like Viridi and announced investee, EasyJoint who will require high quality, compliant product to meet the estimated demands from the European cannabis light and CBD markets.”
About LGC Capital Ltd ( www.lgc-capital.com )
LGC Capital is a leading cannabis investment firm with a focus on the legal global cannabis market. Through its growing portfolio of investment companies, LGC is building a transversal integrated organization of interconnected legal cannabis companies with cultivation, processing and distribution in Australia, Jamaica, Switzerland, Italy, and Canada serving domestic and export markets. LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG) and the US OTC-QB exchange (OTCQB: LGGCF).
Through its partners and assuming pending transactions under review by the TSXV are approved, LGC presently will have interests in Jamaica, Switzerland, Italy, Canada and Australia.
LGC partners currently sell cannabis or cannabis-derived products across Switzerland and Italy under the ONE Premium Cannabis and EasyJoint brands as well as medical cannabis oils in Australia under the Little Green Pharma brand and Hemp-seeds based Medical devices class IIa and Nutritional supplements under Freia Farmaceutici Brands. LGC’s partners’ branded products are available in a variety of formats including medicines, Cosmetics, dry cannabis flower, tinctures, oils and seeds.
For further information please contact:
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Forward Looking Statements
This press release may contain forward-looking statements with respect to LGC and their respective operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC and Evolution Bnk could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the three months ended December 31, 2018, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor Freia has any obligation to update such statements, except to the extent required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CEST | Press release
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect
Banks net position in the Riksbank20.8.2019 16:44:00 CEST | Press release
AUG 20, 2019 SEK MILLION LENDING BORROWING 301
Permission issued to increase the authorised capital of AB Klaipedos nafta subsidiary UAB SGD terminalas20.8.2019 16:00:00 CEST | Press release
With the permission of the Ministry of Finance of the Republic of Lithuania, obtained by AB Klaipedos nafta (hereinafter - the Company), came into force the Company’s board decision to increase the authorised capital of the Company’s subsidiary UAB SGD terminalas in the amount of EUR 10 000. Jonas Lenkšas, Chief Financial Officer, +370 694 80594
PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CEST | Press release
Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to email@example.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: firstname.lastname@example.org Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica
Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CEST | Press release
We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594
SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CEST | Press release
Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: email@example.com Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: firstname.lastname@example.org Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2